Arabinosyl-Atp
Category
Arabinosyl-Atp Brand names, Arabinosyl-Atp Analogs
Arabinosyl-Atp Brand Names Mixture
No information avaliable
Arabinosyl-Atp Chemical_Formula
C10H15N5O5
Arabinosyl-Atp RX_link
http://www.rxlist.com/cgi/generic3/vidarabine.htm
Arabinosyl-Atp fda sheet
Arabinosyl-Atp msds (material safety sheet)
Arabinosyl-Atp Synthesis Reference
No information avaliable
Arabinosyl-Atp Molecular Weight
285.257 g/mol
Arabinosyl-Atp Melting Point
No information avaliable
Arabinosyl-Atp H2O Solubility
No information avaliable
Arabinosyl-Atp State
Solid
Arabinosyl-Atp LogP
-2.115
Arabinosyl-Atp Dosage Forms
No information avaliable
Arabinosyl-Atp Indication
For treatment of chickenpox - varicella, herpes zoster and herpes simplex
Arabinosyl-Atp Pharmacology
Vidarabine is a synthetic purine nucleoside analogue with in vitro and in vivo inhibitory activity against herpes simplex virus types 1 (HSV-1), 2 (HSV-2), and varicella-zoster virus (VZV). The inhibitory activity of Vidarabine is highly selective due to its affinity for the enzyme thymidine kinase (TK) encoded by HSV and VZV. This viral enzyme converts Vidarabine into Vidarabine monophosphate, a nucleotide analogue. The monophosphate is further converted into diphosphate by cellular guanylate kinase and into triphosphate by a number of cellular enzymes. in vitro, Vidarabine triphosphate stops replication of herpes viral DNA. When used as a substrate for viral DNA polymerase, Vidarabine triphosphate competitively inhibits dATP leading to the formation of 'faulty' DNA. This is where Vidarabine triphosphate is incorporated into the DNA strand replacing many of the adenosine bases. This results in the prevention of DNA synthesis, as phosphodiester bridges can longer to be built, destabilizing the strand.
Arabinosyl-Atp Absorption
No information avaliable
Arabinosyl-Atp Toxicity
No information avaliable
Arabinosyl-Atp Patient Information
No information avaliable
Arabinosyl-Atp Organisms Affected
Human Herpes Viruses
